Skip to content
    OTLK
    Earnings call· Jun 2026(Q3 FY26)

    Outlook Therapeutics Q3 FY26 earnings call OTLK

    Aug 14, 2026 Source

    Executive summary

    Outlook Therapeutics Q3 FY26 — FDA Approval of LYTENAVA and U.S. Commercial Launch Preparations

    Outlook Therapeutics achieved a transformative milestone with the FDA approval of LYTENAVA for wet AMD, positioning the company for a significant U.S. commercial launch. The strategy focuses on leveraging bevacizumab's established use while navigating a competitive market with biosimilars and pricing pressures. The company is building out its commercial infrastructure and securing funding to support a measured, high-quality market entry, with a focus on market access and reimbursement, while also strategically assessing its European expansion.

    Highlights

    4

    • FDA approved LYTENAVA as the only FDA-approved ophthalmic formulation of bevacizumab for wet AMD in the U.S.

    • LYTENAVA has the potential to generate more than $500 million in peak annual sales by 2030 in the U.S.

    • Secured $55 million in net proceeds from a public offering to support the U.S. commercial launch.

    • European unit sales increased by 46% in Q3 FY26 compared to Q2 FY26.

    Concerns

    4

    • The U.S. anti-VEGF market is highly competitive, with biosimilars, TKIs, IL-6s, and gene therapies creating pricing pressures.

    • The lack of full funding from the Good Days Foundation may impact patient out-of-pocket costs for LYTENAVA.

    • European market faces challenges including pricing spirals, slow adoption, and regulatory requirements favoring compounding in Germany.

    • Commercial launch requires strong execution, expanding payer partnerships, appropriate access and reimbursement, and reliable supply.

    Guidance & targets

    11
    CategoryTargetConfidence
    Total Net Revenue (first 12 months post-U.S. launch)
    $50M-$75M
    high materiality
    High
    U.S. Launch Revenue Ramp (first 3 months)
    ~10% of first-year net revenues
    medium materiality
    High
    U.S. Launch Revenue Ramp (fourth quarter post-launch)
    ~50% of first-year net revenues
    medium materiality
    High
    Quarterly SG&A Expenses
    Approximately double from current levels
    medium materiality
    High
    Quarterly SG&A Expenses
    Additional increase of approximately 10%
    medium materiality
    High
    R&D Expenses
    Relatively steady
    low materiality
    High
    LYTENAVA Peak Annual Sales (U.S.)
    >$500M
    high materiality
    High
    Permanent J-code Receipt
    April next year
    high materiality
    High
    LYTENAVA WAC Price
    Below $500
    high materiality
    High
    LYTENAVA Market Share (wet AMD)
    30%-35%
    medium materiality
    High
    HCPCS Code Application Submission
    Submission completed
    medium materiality
    High

    Segment performance

    1
    SegmentRevenueYoYQoQMargin
    Europe
    European revenue is improving, with unit sales showing significant quarter-over-quarter growth despite a summer slowdown. The company is right-sizing the team and focusing on strategic expansion due to pricing pressures and regulatory complexities in certain markets like Germany.
    Unit sales growth: 46% QoQ
    		————

    Operational metrics

    10
    Adjusted Net Loss
    $10.9Mvs $15.8M in Q3 FY25
    Q3 FY26

    Excludes certain non-cash and non-recurring items.

    Cash and Cash Equivalents
    $11.2M
    June 30, 2026

    Balance as of quarter end.

    Net Proceeds from Public Offering
    $51.1M
    Subsequent to Q3 FY26

    Expected net proceeds from a $55 million public offering of common stock and accompanying warrants, after underwriting discounts and offering expenses.

    Customer-facing Commercial Personnel
    30
    Planned

    Planned hires for engaging retina specialists and practices across the U.S. for LYTENAVA launch.

    Field Reimbursement Personnel
    20
    Planned

    Planned hires to help practices understand access and reimbursement processes for LYTENAVA.

    LYTENAVA WAC Price
    Below $500
    Planned

    Expected wholesale acquisition cost, aiming to be competitive with biosimilars while reflecting differentiated profile.

    U.S. Anti-VEGF Retina Market Size
    $8.5B
    Annually

    Estimated total market size.

    Off-label Repackaged Bevacizumab Injections (Total U.S.)
    3.6M
    2025

    Estimated injections across all retinal indications.

    Off-label Repackaged Bevacizumab Injections (Wet AMD)
    2.2M
    2025

    Estimated injections specifically for wet AMD.

    Early Adopter Retina Physicians
    Approximately one-third (under 800)
    Current

    Identified through customer segmentation, representing just below 50% of the $500M potential market, primarily using compounded bevacizumab due to payer step-edits.

    Industry KPIs

    2
    MetricValueDetails
    Regulatory approvals filingsFDA Approved
    Clinical trial efficacy safety data41.7%%

    Product announcements

    1
    ProductTypeDetails
    LYTENAVAlaunch

    Risks & headwinds

    4
    Competitive market dynamicsOngoing

    Ongoing decreased pricing pressures for all biosimilars, with new entrants like TKIs, IL-6s, and gene therapies.

    Mitigation: Focused commercial model, differentiated proposition as the only FDA-approved ophthalmic bevacizumab, and strategic market analysis.

    Patient affordability and out-of-pocket costsOngoing

    Impact from changes in funding availability from the Good Days Foundation, potentially increasing patient out-of-pocket costs.

    Mitigation: Thoughtful pricing strategy (below $500/vial), leveraging mechanisms to minimize patient burden, and deploying field reimbursement personnel to assist practices.

    European market challengesOngoing

    Pricing spiral and intense downward pricing pressure leading some biosimilar companies to not commercialize. Regulatory requirements in Germany favor compounding, creating headwinds.

    Mitigation: Right-sizing the European team, strategic market entry, focusing on execution in current markets, and seeking partners for broader expansion.

    Regulatory and reimbursement hurdles for U.S. launchNear-term (Q3 FY26 to April 2027)

    Need for a permanent HCPCS code (by end of Q3 FY26) and a permanent J-code (by April 2027) to ensure broad market access and reimbursement clarity.

    Mitigation: Advancing payer engagement and preparing for timely HCPCS and J-code submissions.

    What to watch in Q4 FY26

    5

    Permanent J-code Receipt

    April next year (April 2027)
    CurrentAnticipated
    TargetReceipt of J-code

    Why it matters

    Crucial for broader adoption and commercial growth, especially for Medicare Advantage plans, and expected to accelerate revenue ramp.

    We anticipate a progressive launch ramp with approximately 10% of first-year net revenues generated during the first three months, moving up to approximately 50% generated during the fourth quarter following launch. We believe the acceleration in the second half of calendar year 2027 corresponds with the permanent J-code we anticipate receiving in April of next year.

    Q&A highlights

    5

    What is the potential upside if repackaged bevacizumab market is disrupted? How many early adopters have been identified and what share of current repackaged use do they represent?

    Management estimates a just under $300 million upside if the compounded market is disrupted. Approximately one-third of retina physicians (under 800) represent nearly 50% of the $500M target, primarily using compounded bevacizumab due to payer step-edits, and are potential early adopters. LYTENAVA aims for 30-35% share of the 2.2 million wet AMD repackaged injections by 2030.

    “Roughly, if there's any disruption in the compounded repackaged bevacizumab or any significant change in its availability, roughly just under a $300 million upside into that in terms of what can potentially happen.”

    asked by Julian Harrison · answered by Robert Jahr

    2 min read6 chapters

    Detailed Narrative

    01

    FDA Approval and Market Opportunity

    Outlook Therapeutics recently secured FDA approval for LYTENAVA, an ophthalmic formulation of bevacizumab for wet AMD, marking a significant transformation for the company. This approval addresses a long-standing need for an FDA-approved version of bevacizumab, a molecule widely used off-label for over two decades. The U.S. anti-VEGF retina market is estimated at $8.5 billion annually, with 3.6 million injections of off-label repackaged bevacizumab in 2025, including 2.2 million for wet AMD. LYTENAVA is positioned as a differentiated option, not competing with branded biosimilars but with the established use of repackaged bevacizumab.

    02

    U.S. Commercial Strategy

    The company's immediate priority is building the commercial infrastructure for a successful U.S. launch. The retina market's high concentration allows for a focused commercial model, targeting practices currently dissatisfied with compounded bevacizumab and those with high utilization. The strategy emphasizes market access and reimbursement, with plans to submit an application for a permanent HCPCS code by end of Q3 FY26 and anticipate a permanent J-code in April 2027. Commercial supply is secured for launch later this year, with scaling processes underway.

    03

    Pricing and Affordability

    Outlook Therapeutics has adopted a thoughtful, research-driven approach to pricing, aiming to support broad access while balancing stakeholder needs. The WAC price for LYTENAVA is expected to be below $500 per vial, competitive with biosimilars while reflecting its differentiated profile. Patient affordability, out-of-pocket costs, and operational realities for buy-and-bill practices have been key considerations, with the company committed to minimizing patient burden.

    04

    Commercial and Medical Affairs Build-out

    The company is building a specialized commercial organization for the retina market, planning to hire approximately 30 customer-facing commercial personnel and 20 field reimbursement personnel. This structure is designed to support physician engagement, education, and navigation of access/reimbursement processes. The medical affairs organization is also expanding to lead scientific exchange, respond to medical information, and support evidence generation, with a focus on real-world data.

    05

    European Market and Global Expansion

    In Europe, the company is focused on execution in existing markets like the UK and preparing for launch in the Netherlands in early 2027, which will serve as a regional distribution hub. Strategic expansion into Switzerland in 2027 is also planned. The company is assessing broader global opportunities in LATAM, Asia, and MENA, seeking partners and evaluating additional bridging studies, with a long-term view that the U.S. will remain the primary commercial opportunity.

    06

    Financial Performance and Capital Raise

    For Q3 FY26, Outlook Therapeutics reported an adjusted net loss of $10.9 million, or $0.09 per share, an improvement from $15.8 million, or $0.44 per share, in Q3 FY25. Cash and cash equivalents stood at $11.2 million as of June 30th. Subsequent to quarter-end, the company announced a $55 million public offering, expected to yield approximately $51.1 million in net proceeds, earmarked for the U.S. commercial launch and general corporate purposes.

    AI-generated summary of the company’s earnings call. Not investment advice.